Changes in Blood Values in Elite Cyclist

Abstract

In 2006, a couple of professional cycling teams initiated their own testing programs. The objective of this study is to describe fluctuations in commonly measured blood parameters among top-level riders. From December 12th 2006 to November 30th 2007, a total of 374 blood samples and 287 urine samples were obtained from 28 elite, male cyclists. Blood was analyzed for hematocrit (Hct), hemoglobin concentration ([Hb]) and % reticulocytes. Seventy-six percent of all samples were collected out-of-competition (OOC). From December 2006 to September 2007, the average Hct and [Hb] decreased by 4.3 percent point and 1.3 g/dL, respectively. After the end of the competitive season, the values increased back to baseline levels. During the Tour de France, the [Hb] decreased by 11.5 %, with individual decreases ranging from 7.0 to 20.6 %. Hct and [Hb] values were lower in-competition (40.9 % and 14.1 g/dL) compared to OOC (43.2 % and 15.0 g/dL) and pre-competition (43.5 % and 14.9 g/dL). Our results suggest that when interpreting blood sample results in an anti-doping context, the sample timing (OOC, pre- or in-competition) and time of year should be kept in mind.

Key words

blood manipulations - elite athletes - biological passport - blood profiles

References

• 1 Ashenden M J, Sharpe K, Damsgaard R, Jarvis L. Standardization of reticulocyte values in an antidoping context.  Am J Clin Pathol. 2004;  121 816-825
• 2 Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart M T, Marion B, Bressolle F. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control.  Med Sci Sports Exerc. 1999;  31 639-645
• 3 Brugnara C. Use of reticulocyte cellular indices in the diagnosis and treatment of hematological disorders.  Int J Clin Lab Res. 1998;  28 1-11
• 4 Damsgaard R, Munch T, Morkeberg J, Mortensen S P, Gonzalez-Alonso J. Effects of blood withdrawal and reinfusion on biomarkers of erythropoiesis in humans: Implications for anti-doping strategies.  Haematologica. 2006;  91 1006-1008
• 5 Gore C J, Parisotto R, Ashenden M J, Stray-Gundersen J, Sharpe K, Hopkins W, Emslie K R, Howe C, Trout G J, Kazlauskas R, Hahn A G. Second-generation blood tests to detect erythropoietin abuse by athletes.  Haematologica. 2003;  88 333-344
• 6 Kalache G R, Sartor M M, Hughes W G. The indirect estimation of hemoglobin concentration in whole blood.  Pathology. 1991;  23 115-117
• 7 Kanstrup I L, Ekblom B. Blood volume and hemoglobin concentration as determinants of maximal aerobic power.  Med Sci Sports Exerc. 1984;  16 256-262
• 8 Kayser B, Mauron A, Miah A. Current anti-doping policy: a critical appraisal.  BMC Med Ethics. 2007;  8 2
• 9 Lippi G, Banfi G, Franchini M, Guidi G C. New strategies for doping control.  J Sports Sci. 2008;  26 441-445
• 10 Lippi G, Franchini M, Guidi G. Haematocrit measurement and antidoping policies.  Clin Lab Haematol. 2002;  24 65-66
• 11 Lippi G, Franchini M, Guidi G C. Tour de chaos.  Br J Sports Med. 2007;  41 625-626
• 12 Lippi G, Salvagno G L, Solero G P, Franchini M, Guidi G C. Stability of blood cell counts, hematologic parameters and reticulocytes indexes on the Advia A120 hematologic analyzer.  J Lab Clin Med. 2005;  146 333-340
• 13 Malcovati L, Pascutto C, Cazzola M. Hematologic passport for athletes competing in endurance sports: a feasibility study.  Haematologica. 2003;  88 570-581
• 14 Morkeberg J, Belhage B, Saltin B, Damsgaard R. Blood profiles in elite cross-country skiers. a 6-year follow-up.  Scand J Med Sci Sports. 2008; 
• 15 Parisotto R, Ashenden M J, Gore C J, Sharpe K, Hopkins W, Hahn A G. The effect of common hematologic abnormalities on the ability of blood models to detect erythropoietin abuse by athletes.  Haematologica. 2003;  88 931-940
• 16 Parisotto R, Gore C J, Emslie K R, Ashenden M J, Brugnara C, Howe C, Martin D T, Trout G J, Hahn A G. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes.  Haematologica. 2000;  85 564-572
• 17 Robinson N, Schattenberg L, Zorzoli M, Mangin P, Saugy M. Haematological analysis conducted at the departure of the Tour de France 2001.  Int J Sports Med. 2005;  26 200-207
• 18 Saris W H, Senden J M, Brouns F. What is a normal red-blood cell mass for professional cyclists?.  Lancet. 1998;  352 1758
• 19 Sawka M N, Convertino V A, Eichner E R, Schnieder S M, Young A J. Blood volume: importance and adaptations to exercise training, environmental stresses, and trauma/sickness.  Med Sci Sports Exerc. 2000;  32 332-348
• 20 Schumacher Y O, Grathwohl D, Barturen J M, Wollenweber M, Heinrich L, Schmid A, Huber G, Keul J. Haemoglobin, haematocrit and red blood cell indices in elite cyclists. Are the control values for blood testing valid?.  Int J Sports Med. 2000;  21 380-385
• 21 Schumacher Y O, Jankovits R, Bultermann D, Schmid A, Berg A. Hematological indices in elite cyclists.  Scand J Med Sci Sports. 2002;  12 301-308
• 22 Sharpe K, Ashenden M J, Schumacher Y O. A third generation approach to detect erythropoietin abuse in athletes.  Haematologica. 2006;  91 356-363
• 23 Thirup P. Haematocrit: within-subject and seasonal variation.  Sports Med. 2003;  33 231-243
• 24 Wilkerson J E, Gutin B, Horvath S M. Exercise-induced changes in blood, red cell, and plasma volumes in man.  Med Sci Sports. 1977;  9 155-158
• 25 Zorzoli M. Blood monitoring in anti-doping setting. Schänzer W, Geyer H, Gotzmann A, Mareck U, eds. Recent advances in doping analysis (13). Köln; Sport und Buchstrauß 2005: 255-264